Citation Impact
Citing Papers
Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol
2012
Mucosal healing in inflammatory bowel diseases: a systematic review
2012 Standout
Trained immunity: A program of innate immune memory in health and disease
2016 StandoutScience
Adherence to HAART Regimens
2003
Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis
2023 StandoutNobel
Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety
2008
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation
2017
Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study
2012
Patient adherence to medical treatment: a review of reviews
2007
Atherosclerotic Vascular Disease in the Autoimmune Rheumatologic Patient
2015
Cytokines in inflammatory bowel disease
2014 Standout
Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease
2005
Risk Factors Associated With Progression to Intestinal Complications of Crohn's Disease in a Population-Based Cohort
2010
The economics of treatment in early rheumatoid arthritis
2009
Cardiovascular Disease and Risk Factors among Psoriasis Patients in Two US Healthcare Databases, 2001–2002
2008
Role of endoscopy in predicting the disease course in inflammatory bowel disease
2010
Infliximab for acute, not steroid-refractory ulcerative colitis
2004
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
2009
Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
2013
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial
2006 Standout
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
2013 Standout
Diagnosis and management of fistulizing Crohn's disease
2009
The association between psoriasis and hypertension
2012
Rheumatoid arthritis
2018 Standout
Psoriasis
2009 Standout
Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial
2007
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
2005
Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial
2015
Rheumatoid arthritis
2016 Standout
Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings
2008
Hidradenitis Suppurativa
2012 Standout
Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled crossover trial
2010
Review article: infliximab therapy for inflammatory bowel disease – seven years on
2006
Intestinal homeostasis and its breakdown in inflammatory bowel disease
2011 StandoutNature
Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing - ASCEND I and II combined analysis
2011
Toward a Personalized Medicine Approach to the Management of Inflammatory Bowel Disease
2014
Importance of mucosal healing in ulcerative colitis
2009
Ulcerative Colitis
2011 Standout
Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation
2006
Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trials
2009
Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn’s Disease
2006
European evidence based consensus for endoscopy in inflammatory bowel disease
2013 Standout
EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis
2009 Standout
Pathogenesis and therapy of psoriasis
2007 StandoutNature
Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease
2011 Standout
A role for mitochondria in NLRP3 inflammasome activation
2010 StandoutNature
Inflammatory bowel disease: clinical aspects and established and evolving therapies
2007 Standout
Crohn's disease
2012 Standout
Induction of Intestinal Th17 Cells by Segmented Filamentous Bacteria
2009 Standout
A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis
2007
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
2009 Standout
Recent insights in the epidemiology of autoimmune diseases: Improved prevalence estimates and understanding of clustering of diseases
2009
CDP571, a humanized monoclonal antibody to tumour necrosis factor‐α, for steroid‐dependent Crohn's disease: a randomized, double‐blind, placebo‐controlled trial
2006
Hospitalization, Surgery, and Readmission Rates of IBD in Canada: A Population-Based Study
2006
Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis
2006
Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents
2012
Appropriateness of Cholesterol Management in Primary Care by Sex and Level of Cardiovascular Risk
2009
Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohnʼs disease
2009
Association Between Disease-Modifying Antirheumatic Drugs and Diabetes Risk in Patients With Rheumatoid Arthritis and Psoriasis
2011
Endoscopic monitoring of infliximab therapy in Crohnʼs disease
2010
Quality of Life Improvements Attributed to Combination Therapy with Oral and Topical Mesalazine in Mild-to-Moderately Active Ulcerative Colitis
2009
Inflammatory bowel disease: cause and immunobiology
2007 Standout
Conformation-sensitive targeting of lipid nanoparticles for RNA therapeutics
2021
The Pathogenesis of Rheumatoid Arthritis
2011 Standout
Inflammatory Bowel Disease
2009 Standout
Mitochondrial Dysfunction in a Patient with Crohn Disease: Possible Role in Pathogenesis
2004
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
2007
How antirheumatic drugs protect joints from damage in rheumatoid arthritis
2008
Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease
2009
Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis
2011
Biological Therapies for Inflammatory Bowel Diseases
2009
Cost of Illness of Crohn??s Disease
2002
Future biologic targets for IBD: potentials and pitfalls
2010
Cytokines sing the blues: inflammation and the pathogenesis of depression
2005 Standout
Glutamate neurotoxicity and diseases of the nervous system
1988 Standout
Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence
2012 Standout
Review article: defining remission in ulcerative colitis
2011
Psoriasis
2015 Standout
Economic Implications of Biological Therapies for Crohn???s Disease
2005
Mucosal healing with methotrexate in Crohn’s disease: a prospective comparative study with azathioprine and infliximab
2011
Safety issues with biological therapies for inflammatory bowel disease
2006
Crohnʼs disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohnʼs disease activity index and endoscopic findings
2007
Mucosal Healing in Inflammatory Bowel Disease: Where Do We Stand?
2010
Interleukin-17 and Type 17 Helper T Cells
2009 Standout
Psoriasis: emerging therapeutic strategies
2005
Crohn's disease
2016 Standout
Ankylosing spondylitis
2007 Standout
Risk of Surgery for Inflammatory Bowel Diseases Has Decreased Over Time: A Systematic Review and Meta-analysis of Population-Based Studies
2013
Review article: remission rates achievable by current therapies for inflammatory bowel disease
2011
Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis
2012
Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab
2009
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
2002 Standout
The long-term efficacy and safety of new biological therapies for psoriasis
2006
Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial
2006
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold
2008
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease
2004
Mucosal Healing in Inflammatory Bowel Disease: Results From a Norwegian Population-Based Cohort
2007
Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease
2016
Epidemiology and comorbidity of psoriasis in children
2009
New Concepts in Intestinal Imaging for Inflammatory Bowel Diseases
2011
Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease
2011
Ulcerative colitis
2016 Standout
Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis
2014
Immunopathogenesis of Psoriasis
2007
Predictors of Temporary and Permanent Work Disability in Patients With Inflammatory Bowel Disease
2013
The Inflammatory Bowel Diseases and Ambient Air Pollution: A Novel Association
2010
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
2010
Rheumatoid arthritis
2010 Standout
Optimizing anti-TNF treatments in inflammatory bowel disease
2013
Crohn's Disease: A Two-Year Prospective Study of the Association Between Psychological Distress and Disease Activity
2004
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease
2007
Mucosal Healing: Impact on the Natural Course or Therapeutic Strategies
2009
Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohnʼs disease: A cautionary tale?
2007
Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial
2008
Clinical implications of mucosal healing for the management of IBD
2009
Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders
2007
Accuracy of Magnetic Resonance Enterography in Assessing Response to Therapy and Mucosal Healing in Patients With Crohn's Disease
2013
A microbial symbiosis factor prevents intestinal inflammatory disease
2008 StandoutNature
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies
2017 Standout
Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts
2011
Mucosal Healing in Crohnʼs Disease
2012
Perianal Fistulizing Crohn’s Disease: A Call to Action
2007
European evidence based consensus on the diagnosis and management of Crohn’s disease: special situations
2006
Regulatory T Cell-Specific Epigenomic Region Variants Are a Key Determinant of Susceptibility to Common Autoimmune Diseases
2020 StandoutNobel
Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction
2011
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
2010
Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold
2014 Standout
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease
2010
Inflammation, metaflammation and immunometabolic disorders
2017 StandoutNature
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
2010 Standout
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
2011 StandoutNature
Evidence for predictive validity of remission on long‐term outcome in rheumatoid arthritis: A systematic review
2009
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
2013
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
2013 Standout
American Gastroenterological Association Institute Technical Review on Corticosteroids, Immunomodulators, and Infliximab in Inflammatory Bowel Disease
2006
Management of Crohn's Disease in Adults
2009 Standout
Infliximab use in Crohn??s disease: impact on health care resources in the UK
2005
Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial
2012
Azathioprine Is Superior to Budesonide in Achieving and Maintaining Mucosal Healing and Histologic Remission in Steroid-Dependent Crohnʼs Disease
2008
Optimizing anti-TNF treatment in inflammatory bowel disease
2004
The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses
2013
Bowel Ultrasound and Mucosal Healing in Ulcerative Colitis
2009
Comorbidities in rheumatoid arthritis
2007
Endoscopic evaluation of patients with inflammatory bowel disease
2008
Therapeutic drug monitoring in patients with inflammatory bowel disease
2014
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
2005 Standout
Adherence to Medication
2005 Standout
The Simplified Disease Activity Index and Clinical Disease Activity Index to Monitor Patients in Standard Clinical Care
2009
Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD
2014
IOIBD technical review on endoscopic indices for Crohn's disease clinical trials
2015
Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohnʼs disease
2009
Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis
2013
Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease
2012
Antidrug antibodies in psoriasis: a systematic review
2013
Regulatory T Cells and Human Disease
2020 StandoutNobel
Inflammatory Bowel Disease: A Canadian Burden of Illness Review
2012
Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial
2013
Randomised clinical trial: delayed-release oral mesalazine 4.8g/day vs. 2.4g/day in endoscopic mucosal healing - ASCEND I and II combined analysis
2011
Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis.
2007
TNF Inhibition Rapidly Down-Regulates Multiple Proinflammatory Pathways in Psoriasis Plaques
2005
British Guideline on the Management of Asthma
2008
[American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease].
2007
Systematic review with meta‐analysis: mucosal healing is associated with improved long‐term outcomes in Crohn's disease
2015
Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease
2016
Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review
2013
TNF‐mediated inflammatory disease
2007 Standout
Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab
2007
Inflammatory Bowel Disease in the United States from 1998 to 2005: Has Infliximab Affected Surgical Rates?
2009
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease
2015
Being surveyed can change later behavior and related parameter estimates
2011 StandoutNobel
Works of Mohan Bala being referenced
Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease
2005
Predictors of joint damage in patients with early rheumatoid arthritis treated with high‐dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial
2006
Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial
2004
Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001–2002
2006
The burden of autoimmune disease: A comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis
2009
Infliximab treatment maintains employability in patients with early rheumatoid arthritis
2006
Annual cost of care for Crohn's disease: a payor perspective
2000
Unemployment and Disability in Patients With Moderately to Severely Active Crohn's Disease
2005
Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: Results from a randomized, placebo‐controlled trial
2006
Infliximab Improves Quality of Life in Patients with Crohn's Disease
2002
The Effects of Infliximab Maintenance Therapy on Health-Related Quality of Life
2003
The Effects of Infliximab Therapy on Health-Related Quality of Life in Ulcerative Colitis Patients
2007
Remission in Patients with Crohn's Disease is Associated with Improvement in Employment and Quality of Life and a Decrease in Hospitalizations and Surgeries
2004
Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis
2007
Inhaled Corticosteroids for Asthma Therapy
2000
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease
2004
Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible united states adults
1998
Valuing Outcomes in Health Care
1998
Comparison of employability outcomes among patients with early or long‐standing rheumatoid arthritis
2008
Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002
2008
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease
2006
Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
2006
Systemic sclerosis prevalence and comorbidities in the US, 2001–2002
2008
Psoriasis: cardiovascular risk factors and other disease comorbidities.
2008
Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis.
2004
Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations.
2008